Table 2 Mucosal vaccines that target mucosal DC subsets
Adjuvant or vaccine type | Route | Target DC subset(s) and effect | Immunity | References |
|---|---|---|---|---|
Flt3 ligand-encoded plasmid | Nasal | CD8α+ DCs | TH2 cytokine production IgA antibody responses | |
CpG oligonucleotide | Nasal | pDCs | TH1 cytokine production IgA antibody responses | |
Plasmodium antigen conjugated to flagellin | Nasal | TLR5+ DCs | Mucosal IgA antibody responses | |
Flagellin+model antigen | Systemic | MLN CD103+ DCs | Intestinal IgA antibody responses | |
Cholera toxin+soluble antigen | Transcutaneous | Langerin+ DCs (MLN) | Intestinal IgA antibody responses | |
LPS-treated Listeriolysin (LLO) 91-99 loaded BM-DC | Tracheal | In vitro-matured bone marrow (BM)-DC | Pulmonary CTL activity | |
pACB-OVA plasmid | Buccal | Langerhans cells | Oral tissue CTL activity | |
Live attenuated influenza or model antigen | Sublingual | Migratory CD8− DCs Resident CD8+ DCs | Mucosal IgA antibody responses | |
Cholera toxin (oral)+Flt3L (intraperitoneal) | Oral | Flt3 ligand expanded DCs | Intestinal IgA antibody responses |
